Recursion Pharmaceuticals Inc (RXRX) - Total Liabilities
Based on the latest financial reports, Recursion Pharmaceuticals Inc (RXRX) has total liabilities worth $314.75 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Recursion Pharmaceuticals Inc net asset momentum to track the company's year-over-year net asset growth rate.
Recursion Pharmaceuticals Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Recursion Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See Recursion Pharmaceuticals Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Recursion Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Recursion Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BEML Limited
NSE:BEML
|
India | Rs31.36 Billion |
|
Henan Hanwei Electronics Co
SHE:300007
|
China | CN¥2.83 Billion |
|
Dalian Zeus Entertainment
SHE:002354
|
China | CN¥648.57 Million |
|
Intershop Holding AG
SW:ISN
|
Switzerland | CHF825.10 Million |
|
Sanoma Oyj
HE:SANOMA
|
Finland | €1.35 Billion |
|
Boston Beer Company Inc
NYSE:SAM
|
USA | $335.62 Million |
|
Adient PLC
NYSE:ADNT
|
USA | $6.80 Billion |
|
Guangdong Baolihua New Energy Stock Co LTD
SHE:000690
|
China | CN¥8.83 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Recursion Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Recursion Pharmaceuticals Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Recursion Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Recursion Pharmaceuticals Inc (2019–2025)
The table below shows the annual total liabilities of Recursion Pharmaceuticals Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $343.26 Million | -17.05% |
| 2024-12-31 | $413.82 Million | +117.50% |
| 2023-12-31 | $190.26 Million | -11.70% |
| 2022-12-31 | $215.48 Million | +219.67% |
| 2021-12-31 | $67.41 Million | -86.65% |
| 2020-12-31 | $504.87 Million | +123.70% |
| 2019-12-31 | $225.70 Million | -- |
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenom… Read more